Welcome to the Desert Angels™. We are a Tucson, Arizona based non-profit organization of accredited investors who seek opportunities to invest in Southwest regional startup or early stage companies. The organization serves as a forum for its over 80 members, who invest individually from their personal funds. Since 2000, Desert Angel members have invested over $41.5 million in more than 99 presenting companies.

Arizona Technology Council Rallies the Technology Community to Successfully Recapitalize the Angel Investment Tax Credit

by Curtis Gunn on May 22nd, 2017 at 5:38pm

Governor Doug Ducey signed House Bill 2191 today, authorizing $2.5 million a year for the next four years into the Angel Investor Tax Credit program for capital infusions into early-stage startup companies. The Arizona Technology Council and its Public Policy Committee were successful in gaining support for the bill by rallying Arizona’s technology community and leading efforts to lobby for recapitalization.

“The recapitalization of the Angel Investor Tax Credit program has been a top priority for the Council since the original $20 million in tax credits ran out in 2015,” said Steven G. Zylstra, president and CEO of the Arizona Technology Council. “The initial program showed a direct return on investment of more than 2.2 to 1 in tax revenue. Today’s signing is a major success for our startup technology community and reinforces that Arizona is open for business.”

Read full article here

Comment

Filed under: Uncategorized

Tucson’s Vector successfully launches rocket

by Curtis Gunn on May 17th, 2017 at 9:11pm

Vector, a Tucson-based startup that plans to launch micro-satellites in space, successfully launched a prototype of its Vector-R rocket for the first time Wednesday from a site near Mohave, California.

The flight makes Vector the first of a cadre of emerging small-launch companies to successfully test a launch vehicle.

Read full article here

Comment

Filed under: Uncategorized

Tucson Tech: Rocket firm surging ahead on all fronts

by Curtis Gunn on April 22nd, 2017 at 10:51pm

The Tucson-based rocket company Vector is hurtling ahead on all fronts as it moves to build out its Tucson factory and start commercial rocket launches as soon as next year.

Founded just last year, Vector is building small rockets to launch a growing class of micro-satellites into orbit.

The company was founded by a group of space veterans including CEO Jim Cantrell, an alumnus of Elon Musk’s SpaceX, and John Garvey, a veteran of space programs at Boeing and McDonnell Douglas who ran his own spacecraft company for 16 years before merging it with Vector.

Read full article here

Comment

Filed under: Uncategorized

Tucson aerospace startup raises $4.5 million, hiring up to 100 employees

by Curtis Gunn on April 19th, 2017 at 10:53pm

Tucson-based Vector, developer of what it calls the world’s smallest satellite launcher rocket, has raised $4.5 million in a bridge round.

The aerospace startup’s bridge round — between its seed and Series A rounds — was raised from a majority of Arizona investors, including Tucson-based Desert Angels; Arizona Technology Investors and Kurrent Investment from Phoenix; and angel investors from Tucson.

Read full article here

Comment

Filed under: Uncategorized

HTG Molecular Diagnostics and Daiichi Sankyo Complete Master Services Agreement

by Curtis Gunn on April 17th, 2017 at 9:00pm

HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that it has entered into a master services agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for work to be performed in HTG’s VERI/O laboratory. The initial project includes the development of a custom assay for the detection of nearly 3,000 mRNA targets using the HTG EdgeSeq technology.

When completed, the custom assay will be used to generate data from formalin-fixed, paraffin-embedded (FFPE) samples. Daiichi Sankyo plans to use these data to identify a tumor profiling assay for future studies under the agreement. Daiichi Sankyo also has engaged HTG to process several hundred FFPE samples using the HTG EdgeSeq ALKPlus Assay EU in a research use only mode for exploratory research on new, potential therapeutic biomarkers.

Read full article here

Comment

Filed under: Uncategorized

The NHLBI Grants NuvOx Pharma a 300K Grant to Study the Effects of Their Oxygen Therapeutic on Myocardial Infarction in a Pig Model

by Curtis Gunn on April 14th, 2017 at 9:08pm

Tucson, AZ, April 14, 2017 –(PR.com)– Evan Unger, MD, President and CEO of NuvOx Pharma, announced that NuvOx Pharma has been awarded a grant from the National Heart, Lung, and Blood Institute (NHLBI) entitled “Dodecafluoropentane Prevents Ischemia Reperfusion Injury in Contemporary Acute Myocardial Infarction Management,” for a total of $317,743. This grant will be used to support research to study NVX-308 as a cardioprotectant to reduce damage to the heart following myocardial infarction.

Read full article here

Comment

Filed under: Uncategorized

FDA Allows NuvOx Pharma to Run a Phase II Clinical Trial in Brain Cancer

by Curtis Gunn on April 13th, 2017 at 9:03pm

TUCSON, Ariz.–(BUSINESS WIRE)–Nuvox Pharma announces that the FDA has allowed an Investigational New Drug (IND) application to initiate a Phase II clinical trial for its oxygen therapeutic, NVX-108, in patients with the hypoxic solid brain tumor, glioblastoma multiforme (GBM). NVX-108 is an injectable drug that travels through the bloodstream arriving first at the lungs to pick up oxygen and finally to hypoxic tissue where it passively delivers the oxygen. It is designed to reduce tumor hypoxia in order to make tumors more sensitive to radiation therapy and chemotherapy.

The clinical trial’s principal investigator, Baldassarre Stea, MD, PhD, said, “Tumor hypoxia is known to be a problem in many tumor types, including GBM. Hypoxic tumors are resistant to radiation therapy and certain kinds of chemotherapy. By increasing tumor oxygen levels, NVX-108 is designed to improve the effectiveness of these therapies in order to kill cancer cells more effectively and increase patient survival. Clinical trials are needed to see if NVX-108 can become approved by regulators.”

Read full article here

Comment

Filed under: Uncategorized

Tempe tech startup raises $1 million in seed round

by Curtis Gunn on March 22nd, 2017 at 4:44pm

Tempe tech startup Prospectify.io has raised $1 million in a seed round to expand its staff, its software and its customers.

Prospectify helps business-to-business salespeople identify the right companies to target, and the relevant contacts at those companies, while delivering messaging to them when they’re most likely to buy, said Matt Ekstrom, co-founder and chief revenue officer.

“Our customers buy from us the ability to search a database of companies based on 40 different data points on companies, from their business model to revenue, to the technology they use,” Ekstrom said. “Then pair that with the type of prospect profiles they’re looking for.”

Read full article here

Comment

Filed under: Uncategorized

NuvOx Pharma and the University of Arkansas Initiate Phase Ib/II Clinical Trial in Stroke

by Curtis Gunn on March 6th, 2017 at 6:10pm

NuvOx Pharma announces that the first patients have been dosed in a Phase Ib/II clinical trial for NVX-208, an oxygen therapeutic being developed for acute ischemic stroke. The trial is being performed at the University of Arkansas for Medical Sciences in Little Rock, Arkansas, under the direction of Dr. William Culp, the Jonathan Fitch Distinguished Chair in Stroke. Culp said, “We have studied NVX-208 in a number of pre-clinical stroke models and found that administration of NVX-208 decreases the brain damage from stroke by over 80%. The only approved drug to treat stroke is the thrombolytic drug t-PA, which has a risk of bleeding and is approved for use only up to 3 hours following stroke. Administration of NVX-208 prior to t-PA extended the time window of efficacy to at least nine hours.”

Read full article here

Comment

Filed under: Uncategorized

HTG Molecular Diagnostics Unveils New Direct-Target Sequencing Chemistry to Launch in First Quarter 2017

by Curtis Gunn on March 2nd, 2017 at 6:07pm

HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM)(“HTG”), a provider of instruments, reagents and services for molecular profiling applications announced that its new direct-target sequencing chemistry will be available in the company’s VERI/O laboratory as a service offering beginning in the first quarter of 2017. The new chemistry is designed for direct sequencing of specified DNA and, in the future, RNA targets with the same high sensitivity and specificity as the company’s current HTG EdgeSeq chemistry applications. The initial panel planned for the VERI/O laboratory will detect common mutations in the EGFR, KRAS and BRAF genes for retrospective research studies especially from small and difficult samples, such as formalin-fixed, paraffin-embedded (FFPE) tissue.

Read full article here

Comment

Filed under: Uncategorized